Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05835999 · ClinicalTrials.gov registry record · Phase 2
Everolimus Aging Study
A Phase 2 study of Aging and Insulin Resistance, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT05835999: Active Phase 2 study of Aging and Insulin Resistance, sponsored by University of Wisconsin, Madison.
NCT05835999 is a Phase 2 study of Aging and Insulin Resistance that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 106 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05835999, a Phase 2 study of Aging and Insulin Resistance, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.
Primary Outcome
Change (pre to post) in peripheral insulin sensitivity measured by glucose disposal rate relative to circulating insulin during a dual tracer 75g oral glucose tolerance test (OGTT).
Conditions Studied
Interventions
- DRUG Everolimus 0.5 MG once per day
- DRUG Everolimus 5 MG once per week
- DRUG Placebo once per day
- DRUG Placebo once per week
Study Locations (1)
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT05835999 still lists
NCT05835999 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Aging appearing as the primary indexed condition, and to 4 interventions - of which Everolimus 0.5 MG once per day is the first listed.
NCT05835999 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05835999 about?
NCT05835999 is a clinical study titled "Everolimus Aging Study". The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomi...
What is the current status of trial NCT05835999?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2023-03-24. Estimated completion is 2026-09.
What conditions does trial NCT05835999 study?
This clinical trial studies the following conditions: Aging, Insulin Resistance.
What interventions are being tested in trial NCT05835999?
The interventions under investigation include: Everolimus 0.5 MG once per day (DRUG), Everolimus 5 MG once per week (DRUG), Placebo once per day (DRUG), Placebo once per week (DRUG).
Who is sponsoring clinical trial NCT05835999?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05835999 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05835999's enrollment target sits among peer trials
106 81st of 262 higher than 181 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Empagliflozin Reversal of Arterial StiffnEss in Aging
RECRUITING · Phase 2
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
Acetate and Age-associated Arterial Dysfunction
RECRUITING · Phase 2
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI